Page last updated: 2024-12-08
isofloridoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
isofloridoside: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
isofloridoside : A galactosylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding alpha-D-galactopyranoside. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 193395 |
CHEBI ID | 147787 |
MeSH ID | M0084090 |
Synonyms (10)
Synonym |
---|
isofloridoside |
CHEBI:147787 |
2,3-dihydroxypropyl alpha-d-galactopyranoside |
3-o-galactopyranosylglycerol |
wurcs=2.0/2,2,1/[hxh][a2112h-1a_1-5]/1-2/a3-b1 |
4649-46-1 |
(2s,3r,4s,5r,6r)-2-(2,3-dihydroxypropoxy)-6-(hydroxymethyl)oxane-3,4,5-triol |
3-o-galactopyranosyl-sn-glycerol |
d-glyceryl beta-galactopyranoside |
alpha-d-galactopyranosyl-(1-1)-glycerol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
alpha-D-galactoside | Any D-galactoside having alpha-configuration at its anomeric centre. |
galactosylglycerol | A glycosylglycerol in which the glycosyl residue specified is galactose. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (15.38) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 3 (23.08) | 29.6817 |
2010's | 5 (38.46) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.69%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (92.31%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |